American scientists from the Johns Hopkins University School of Medicine changed one of the proteins in immune lymphocytes (also known as T cells), making them more resilient and capable of destroying cancerous tumors and infections at the expense of the patient’s immunity. The study was published in the scientific journal magazine JCI Insight.
“Maximizing the effectiveness of T-cell-based therapies remains a critical challenge. Lead author Dr. David Kass said, “Boosting T-cell function offers a promising pathway to improve cancer immunotherapy and potentially treat a wide range of infectious and other diseases. “We found a strong way,” he said.
Scientists have discovered a mutation in the TSC2 protein gene that causes it to respond more actively to viruses and cancer antigens. According to the expert, the change worked as a “volume control”: it did not manifest itself in the absence of targets for the leukocyte, but when a threat appeared, it stimulated the cell to fight it more actively.
The researchers also found that the modified T cells proliferate in large numbers during the initial immune response and then persist in the body for a long time.
The researchers plan to conduct further studies on solid tumors in lung, liver and colon cancers, where it is more difficult to achieve complete success with lymphocyte-based therapy compared to leukemia and other blood cancers.
Previous scientists approached Creating an implant to detect and treat cancer.
Source: Gazeta
Barbara Dickson is a seasoned writer for “Social Bites”. She keeps readers informed on the latest news and trends, providing in-depth coverage and analysis on a variety of topics.